• 1. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Peptides
• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Peptides

Introduction to H-Gly-Leu-Leu-Gly-OH and Its Significance in Modern Research

H-Gly-Leu-Leu-Gly-OH, a synthetic peptide with the CAS number 104845-51-4, has garnered significant attention in the field of chemical and biomedical research due to its unique structural properties and potential applications. This peptide, characterized by its sequence of glycine, leucine, leucine, and glycine residues terminated by a carboxyl group, represents a cornerstone in the development of novel therapeutic agents and biochemical probes.

The structural simplicity of H-Gly-Leu-Leu-Gly-OH belies its remarkable versatility. The presence of glycine residues at both the N-terminal and C-terminal ends contributes to its flexibility, making it an ideal candidate for various biochemical interactions. Leucine residues, known for their hydrophobicity, enhance the peptide's solubility in organic solvents while maintaining stability in aqueous environments. This balance is crucial for its application in drug delivery systems and biomimetic scaffolds.

Recent advancements in peptide-based drug design have highlighted the importance of such sequences in modulating biological pathways. H-Gly-Leu-Leu-Gly-OH has been extensively studied for its role in inhibiting proteolytic enzymes, which are implicated in various pathological conditions such as cancer and inflammation. The peptide's ability to mimic natural substrates of these enzymes has opened new avenues for targeted therapy.

In the realm of nanotechnology, H-Gly-Leu-Leu-Gly-OH has been utilized as a building block for constructing functionalized nanoparticles. These nanoparticles, equipped with the peptide's targeting ligands, have shown promise in enhancing the efficacy of drug delivery systems. For instance, studies have demonstrated their potential in delivering anticancer agents directly to tumor sites, thereby reducing systemic toxicity and improving therapeutic outcomes.

The peptide's applications extend to regenerative medicine as well. Researchers have explored its use as a scaffold for tissue engineering, leveraging its biocompatibility and ability to promote cell adhesion. By integrating growth factors or other bioactive molecules into H-Gly-Leu-Leu-Gly-OH-based scaffolds, scientists have achieved significant progress in creating functional tissue constructs that can be used for surgical reconstruction or organ transplantation.

Furthermore, H-Gly-Leu-Leu-Gly-OH has found utility in diagnostic assays. Its unique spectroscopic properties make it an excellent candidate for developing biosensors that can detect specific biomarkers associated with diseases. These biosensors offer high sensitivity and selectivity, enabling early detection and accurate monitoring of pathological conditions.

The synthesis of H-Gly-Leu-Leu-Gly-OH is another area where significant progress has been made. Advances in solid-phase peptide synthesis (SPPS) have enabled the production of high-purity peptides with greater efficiency and scalability. This has facilitated the exploration of novel derivatives and modifications of the peptide sequence, expanding its therapeutic potential.

Future research directions for H-Gly-Leu-Leu-Gly-OH include exploring its role in modulating immune responses and developing it as an adjuvant for vaccines. Preliminary studies suggest that the peptide can enhance antigen presentation by immune cells, thereby improving vaccine efficacy against infectious diseases.

In conclusion, H-Gly-Leu-Leu-Gly-OH (CAS number 104845-51-4) is a multifaceted peptide with broad applications in pharmaceuticals, nanotechnology, regenerative medicine, diagnostics, and immunology. Its unique structural properties and biological activities make it a valuable tool for advancing research and developing innovative therapeutic strategies. As our understanding of its mechanisms continues to grow, so too will its impact on addressing some of the most pressing challenges in modern medicine.

• 3303-34-2(L-Alanyl-L-leucine)
• 1999-42-4(DL-Alanyl-DL-leucine)
• 13588-95-9(H-Leu-val-OH)
• 183449-57-2(L-Alanine,5-oxo-L-prolyl-L-phenylalanyl-L-arginyl-L-histidyl-L-a-aspartyl-L-serylglycyl-L-tyrosyl-L-a-glutamyl-L-valyl-L-histidyl-L-histidyl-L-glutaminyl-L-lysyl-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-L-alanyl-L-a-glutamyl-L-a-aspartyl-L-valylglycyl-L-seryl-L-asparaginyl-L-lysylglycyl-L-alanyl-L-isoleucyl-L-isoleucylglycyl-L-leucyl-L-methionyl-L-valylglycylglycyl-L-valyl-L-valyl-L-isoleucyl-)
• 17665-02-0(L-Leucyl-D-leucine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)